COVID-19-Associated Pulmonary Mucormycosis

Area of Science:

• Infectious Diseases
• Pulmonology
• Mycology

Background:

• COVID-19 pandemic facilitated an epidemic of COVID-19-associated mucormycosis (CAM).
• Pulmonary mucormycosis (CAPM) was likely under-recognized due to limited lower airway sampling and diagnostic facilities.
• CAM poses a significant threat, particularly in immunocompromised individuals.

Purpose of the Study:

• To review the epidemiology and management strategies for COVID-19-associated pulmonary mucormycosis (CAPM).
• To highlight the high mortality rate of CAPM and the need for early diagnosis and intervention.

Main Methods:

• Review of existing literature on CAPM epidemiology and clinical management.
• Discussion of diagnostic modalities, including gold standards and emerging molecular/serological methods.
• Analysis of treatment outcomes for combined medical and surgical therapies versus standalone medical treatment.

Main Results:

• CAPM is a severe condition with mortality rates up to 80% without prompt diagnosis and treatment.
• Histopathology and cultures are gold standards, but molecular and serological methods are gaining interest for critically ill patients.
• Combined medical and surgical treatment shows more promise than medical therapy alone.

Conclusions:

• Early clinical suspicion and prompt treatment are vital for reducing CAPM mortality.
• Development and validation of reliable biomarkers and molecular diagnostics are urgently needed for early CAPM detection.
• Prudent use of steroids and glycemic control are key preventative measures for COVID-19 patients at risk.